<DOC>
	<DOCNO>NCT02465359</DOCNO>
	<brief_summary>The investigator use self administer subcutaneous IG patient CIDP require IVIG . Safety , efficacy , patient satisfaction examine .</brief_summary>
	<brief_title>Subcutaneous Immunoglobulin CIDP</brief_title>
	<detailed_description>Chronic inflammatory demyelinate polyneuropathy ( CIDP ) autoimmune neurological disorder cause limb weakness numbness . Many patient require immunosuppressant plasma exchange ( PLEX ) control symptom . Intravenous immunoglobulin ( IVIG ) also effective treatment ( Hughes et al , 2006 &amp; 2008 ; Hughes , 2009 ; Cocito et al , 2010 ) , American Academy Neurology ( AAN ) guideline recommend offer long-term treatment CIDP ( Patwa et al , 2012 ) . While effective , IVIG cause systemic side effect 5 % patient . These side effect include rash , pruritus , myalgia , fever , chill , headache , low back pain , nausea , vomit , change blood pressure heart rate , renal failure , aseptic meningitis ( Berger , 2008 ) . For many patient chronically treat IVIG , venous access may problem time . An alternative subcutaneous ( SC ) route , use since 1980 primary immune deficiency disorder treatment choice condition Scandinavia England ( Radinsky et al , 2003 ) . As compare IV route , SC route maintain high trough level immunoglobulin , increase patient independence , reduces systemic side-effects , well tolerate pregnant sensitize IgA ( Radinsky et al , 2003 ) . In review side effect associate 33,168 SCIG infusion , severe anaphylactoid reaction occur ( Gardulf et al , 1995 ) . Patients self-administer medication , hence , overall cost may reduce . A retrospective study 28 child primary immunodeficiency Canada show mean difference cost IVIG SCIG study period ( 1 year IVIG 1 year SCIG ) $ 4,346 favor SCIG ( Ducruet et al , 2011 ) . A US $ 10,100 reduction cost per year per patient associate SCIG use also report Gardulf et al ( 1995 ) Sweden . Disadvantages SCIG include frequent infusion local reaction sit infusion ( transient swelling , soreness , redness , induration , local heat , itch ) 1 % patient .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>To qualify , patient must CIDP persistence significant symptom ( 2 follow ) : Weakness limb , Motor fatigue significant interfere ADL work , Paresthesia sufficient severity require medication , Sensory impairment , Walking impairment , AND require IVIG control symptom . 1 . Thrombocytopenia bleed disorder , 2 . Anticoagulation therapy , 3 . Severe anaphylactoid reaction IVIG , 4 . Cancer , 5 . Pregnancy , 6 . Breastfeeding , 7 . Renal insufficiency failure , 8 . Congestive heart failure , 9 . Psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>